AQR Capital Management LLC Has $207.37 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• AQR Capital Management LLC increased its stake in Gilead Sciences by 2.8%, owning approximately $207.37 million worth of 1,864,670 shares as of the latest SEC filing.
• Gilead Sciences' CEO, Daniel O'Day, sold 10,000 shares for $1,139,400, reducing his ownership by 1.62% to 605,725 shares valued at over $69 million.
• Analysts have upgraded Gilead's stock ratings, with several firms raising their target prices, contributing to an average consensus price target of $115.39.

AQR Capital Management LLC grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 2.8% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,864,670 shares of the biopharmaceutical company's stock after buying an additional 51,116 shares during the period. AQR Capital Management LLC owned approximately 0.15% of Gilead Sciences worth $207,370,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in GILD. Ariel Investments LLC lifted its position in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company's stock worth $48,229,000 after purchasing an additional 30,630 shares during the last quarter. Atalanta Sosnoff Capital LLC lifted its position in shares of Gilead Sciences by 10.3% during the 1st quarter. Atalanta Sosnoff Capital LLC now owns 2,921 shares of the biopharmaceutical company's stock worth $327,000 after purchasing an additional 273 shares during the last quarter. Advisors Asset Management Inc. lifted its position in shares of Gilead Sciences by 6.4% during the 1st quarter. Advisors Asset Management Inc. now owns 239,934 shares of the biopharmaceutical company's stock worth $26,885,000 after purchasing an additional 14,358 shares during the last quarter. Aprio Wealth Management LLC raised its holdings in Gilead Sciences by 57.0% in the 1st quarter. Aprio Wealth Management LLC now owns 12,189 shares of the biopharmaceutical company's stock valued at $1,366,000 after acquiring an additional 4,423 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its holdings in Gilead Sciences by 7.4% in the 1st quarter. Federation des caisses Desjardins du Quebec now owns 95,135 shares of the biopharmaceutical company's stock valued at $10,665,000 after acquiring an additional 6,563 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Buying and Selling

In other news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the sale, the chief executive officer owned 605,725 shares in the company, valued at $69,016,306.50. The trade was a 1.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of the business's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 82,000 shares of company stock worth $9,371,330 over the last 90 days. 0.27% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on GILD shares. Daiwa America upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a report on Friday, July 25th. UBS Group increased their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. Truist Financial upgraded Gilead Sciences from a "hold" rating to a "buy" rating and increased their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Finally, Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 target price on the stock in a report on Tuesday, August 19th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Up 0.2%

Shares of GILD opened at $112.99 on Thursday. The business's fifty day moving average price is $113.39 and its two-hundred day moving average price is $109.76. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $140.20 billion, a price-to-earnings ratio of 22.51, a PEG ratio of 0.70 and a beta of 0.36. Gilead Sciences, Inc. has a 52 week low of $77.74 and a 52 week high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. Gilead Sciences's dividend payout ratio (DPR) is presently 62.95%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.